CD19 and neoplasm: identified a small population of brain mural cells expressing CD19 that might serve as potential off-tumor targets for CAR T immunotherapies and could play a role in the pathophysiology of ICANS,11 next to or on top of cytokine-induced dysfunction of the blood-brain barrier and transmigration of inflammatory cells.12